Related references
Note: Only part of the references are listed.SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
Chenguang Li et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Glycogen Synthase Kinase-3α Promotes Fatty Acid Uptake and Lipotoxic Cardiomyopathy
Michinari Nakamura et al.
CELL METABOLISM (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
MiR-30c/PGC-1β protects against diabetic cardiomyopathy via PPARα
Zhongwei Yin et al.
CARDIOVASCULAR DIABETOLOGY (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
Narjes Nasiri-Ansari et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
Kenneth W. Mahaffey et al.
CIRCULATION (2018)
Effects of SGLT2 Inhibitors on Circulating Stem and Progenitor Cells in Patients With Type 2 Diabetes
Benedetta Maria Bonora et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
Laween Uthman et al.
DIABETOLOGIA (2018)
Long-term Prediction of Cardiovascular Outcomes by Circulating CD34+ and CD34+ CD133+ Stem Cells in Patients With Type 2 Diabetes
Gian Paolo Fadini et al.
DIABETES CARE (2017)
Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target
Alessandra Di Franco et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Endothelial Progenitors: A Consensus Statement on Nomenclature
Reinhold J. Medina et al.
STEM CELLS TRANSLATIONAL MEDICINE (2017)
Stearic acid at physiologic concentrations induces in vitro lipotoxicity in circulating angiogenic cells
Valentina Spigoni et al.
ATHEROSCLEROSIS (2017)
Platelets and von Willebrand factor in atherogenesis
Melinda D. Wu et al.
BLOOD (2017)
Levels of Circulating Progenitor Cells, Cardiovascular Outcomes and Death A Meta-Analysis of Prospective Observational Studies
Mauro Rigato et al.
CIRCULATION RESEARCH (2016)
The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
Simon A. Hawley et al.
DIABETES (2016)
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Naveed Sattar et al.
DIABETOLOGIA (2016)
Involvement of circulating endothelial progenitor cells in carotid plaque growth and vulnerability
Daina Kashiwazaki et al.
JOURNAL OF NEUROSURGERY (2016)
Endothelial Progenitor Cells for Diagnosis and Prognosis in Cardiovascular Disease
Caterina Oriana Aragona et al.
STEM CELLS INTERNATIONAL (2016)
Na+/H+ exchanger in the regulation of platelet activation and paradoxical effects of cariporide
He Benny Chang et al.
EXPERIMENTAL NEUROLOGY (2015)
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
Caroline Bonner et al.
NATURE MEDICINE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system
Antonis Koussounadis et al.
SCIENTIFIC REPORTS (2015)
Effects of TiO2 and Co3O4 Nanoparticles on Circulating Angiogenic Cells
Valentina Spigoni et al.
PLOS ONE (2015)
Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2
Sreeneeranj Kasichayanula et al.
CLINICAL PHARMACOKINETICS (2014)
N-3 PUFA increase bioavailability and function of endothelial progenitor cells
Valentina Spigoni et al.
FOOD & FUNCTION (2014)
Inflammation and thrombosis in cardiovascular disease
Prabhakara Nagareddy et al.
CURRENT OPINION IN HEMATOLOGY (2013)
SLC9/NHE gene family, a plasma membrane and organellar family of Na+/H+ exchangers
Mark Donowitz et al.
MOLECULAR ASPECTS OF MEDICINE (2013)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Tim Heise et al.
DIABETES THERAPY (2013)
Insights into the regulation of protein abundance from proteomic and transcriptomic analyses
Christine Vogel et al.
NATURE REVIEWS GENETICS (2012)
Protein Kinase C ε Expression in Platelets from Patients with Acute Myocardial Infarction
Cecilia Carubbi et al.
PLOS ONE (2012)
Pioglitazone Improves In Vitro Viability and Function of Endothelial Progenitor Cells from Individuals with Impaired Glucose Tolerance
Valentina Spigoni et al.
PLOS ONE (2012)
Bone Marrow Endothelial Progenitors Augment Atherosclerotic Plaque Regression in a Mouse Model of Plasma Lipid Lowering
Longbiao Yao et al.
STEM CELLS (2012)
Guidelines for the laboratory investigation of heritable disorders of platelet function
Paul Harrison et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Platelet abnormalities in diabetes mellitus
Jose Luis Ferreiro et al.
DIABETES & VASCULAR DISEASE RESEARCH (2010)
Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009
R. A. DeFronzo
DIABETOLOGIA (2010)
Role of Platelets in Atherothrombosis
Lisa K. Jennings
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Endothelial progenitor cells and their potential clinical implication in cardiovascular disorders
A. Zeoli et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2009)
Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis
Andreas Schaefer et al.
CURRENT VASCULAR PHARMACOLOGY (2008)
Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events -: Proof of concept for the clinical importance of endogenous vascular repair
C Schmidt-Lucke et al.
CIRCULATION (2005)
Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis
R Corti et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2004)
IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis
AH Li et al.
JOURNAL OF IMMUNOLOGY (2003)
Effects of the NHE-1 inhibitor cariporide alone or together with the P2Y(12) antagonist AR-C 69331 MX on CD62p expression and formation of platelet-leukocyte aggregates
U Klinkhardt et al.
THROMBOSIS RESEARCH (2003)
Platelets in atherothrombosis
ZM Ruggeri
NATURE MEDICINE (2002)
NHE blockade inhibits chemokine production and NF-κB activation in immunostimulated endothelial cells
ZH Németh et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2002)
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes
Jo Vandesompele et al.
GENOME BIOLOGY (2002)
Inhibition of the Na+/H+ antiporter suppresses IL-12 p40 production by mouse macrophages
ZH Németh et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2001)
Share Paper
